In meta-analysis, the results confirmed that Danhong injection, as an adjuvant treatment, performed better in improving clinical efficacy, lung function (FEV1/FVC%, FVC(L)), analysis of the arterial blood gas (DLCO, PaO2), inflammatory cytokines (TNF-α, TGF-β1), and serum cytokines associated with pulmonary fibrosis (HA, LN, PCIII, ColIII, BUN), which is suggesting that Danhong injection has certain advantages and curative effects as a alternative drug for the treatment of IPF. The gene discussed is TGFB1; the disease is pulmonary fibrosis.